CervoMed Inc. (CRVO)
NASDAQ: CRVO · IEX Real-Time Price · USD
24.99
+0.39 (1.59%)
At close: Apr 25, 2024, 4:00 PM
24.98
-0.01 (-0.04%)
After-hours: Apr 25, 2024, 6:40 PM EDT
CervoMed Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CervoMed stock has a target of 65, which predicts an increase of 160.10% from the current stock price of 24.99.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for CervoMed is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $50 → $65 | Strong Buy | Maintains | $50 → $65 | +160.10% | Apr 8, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +100.08% | Feb 15, 2024 |
Financial Forecast
Revenue This Year
8.98M
from 7.14M
Increased by 25.63%
Revenue Next Year
7.24M
from 8.98M
Decreased by -19.32%
EPS This Year
-1.64
from -0.82
EPS Next Year
-2.87
from -1.64
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 9.2M | 7.5M | n/a |
| Avg | 9.0M | 7.2M | n/a |
| Low | 8.6M | 7.0M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 29.3% | -16.9% | - |
| Avg | 25.6% | -19.3% | - |
| Low | 20.7% | -22.5% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.69 | -2.95 | -4.13 |
| Avg | -1.64 | -2.87 | -4.01 |
| Low | -1.58 | -2.75 | -3.85 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.